...
首页> 外文期刊>Journal of Cancer Research and Clinical Oncology >Epidermal growth factor receptor gene mutation, amplification and protein expression in malignant pleural mesothelioma
【24h】

Epidermal growth factor receptor gene mutation, amplification and protein expression in malignant pleural mesothelioma

机译:恶性胸膜间皮瘤表皮生长因子受体基因突变,扩增及蛋白表达

获取原文
获取原文并翻译 | 示例

摘要

Epidermal growth factor receptor (EGFR) is overexpressed in a variety of epithelial malignancies. In lung cancer cases, EGFR gene mutation at the kinase domain and EGFR gene amplification are reported to be predictors of the response to EGFR tyrosine kinase inhibitors. In malignant pleural mesothelioma (MPM), the role of EGFR is less clear. We studied EGFR gene mutation, amplification and protein expression in 25 Japanese patients with MPM. None had previously reported EGFR mutations detected by the TaqMan PCR assay. Using immunohistochemistry, 8/25 (32%) cases were positive for the EGFR protein. The cases of sarcomatous type and desmoplastic type were all negative. Fluorescence in situ hybridization analysis revealed three low polysomy cases and one high polysomy case. The low polysomy cases included one biphasic type and two epithelial types, and the high polysomy case was epithelial type. These four cases expressed EGFR protein. In MPM, EGFR seems to play a role in a limited subset of patients. To identify possible candidates for EGFR tyrosine kinase in inhibitor therapy, the information on the EGFR gene status may be valuable.
机译:表皮生长因子受体(EGFR)在多种上皮恶性肿瘤中过表达。在肺癌病例中,据报道激酶结构域的EGFR基因突变和EGFR基因扩增是对EGFR酪氨酸激酶抑制剂反应的预测因子。在恶性胸膜间皮瘤(MPM)中,EGFR的作用尚不清楚。我们研究了25名日本MPM患者的EGFR基因突变,扩增和蛋白表达。以前没有人报道过T​​aqMan PCR分析检测到的EGFR突变。使用免疫组织化学方法,有8/25(32%)病例的EGFR蛋白阳性。肉瘤型和增生型均为阴性。荧光原位杂交分析显示3例低多态性病例和1例高多态性病例。低多体型病例包括一种双相型和两种上皮型,高多体型病例为上皮型。这四个病例表达EGFR蛋白。在MPM中,EGFR似乎在一部分患者中起作用。为了确定抑制剂治疗中EGFR酪氨酸激酶的可能候选者,有关EGFR基因状态的信息可能很有价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号